Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Laparoscopic fundoplication and paraesophageal hernia repair. Main billing specialty: general surgery.
Medicare fee-for-service antireflux & hiatal hernia surgery cases in the 42 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (180 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 40 | 2,078−1.9%/yr | −1.9%/yr | 1.01.3× | 0% | 2,490 in 2030+3%/yr |
| California | 37 | 2,040+1.2%/yr | +1.2%/yr | 0.60.8× | 0% | 2,990 in 2030+6.6%/yr |
| Florida | 30 | 1,735−2.6%/yr | −2.6%/yr | 0.81.0× | 0% | 2,220 in 2030+4.2%/yr |
| Pennsylvania | 16 | 1,062−0.9%/yr | −0.9%/yr | 0.81.0× | 0% | 960 in 2030−1.6%/yr |
| New York | 15 | 966−1.7%/yr | −1.7%/yr | 0.50.7× | 0% | 1,220 in 2030+4%/yr |
| Ohio | 13 | 867−1.9%/yr | −1.9%/yr | 0.81.1× | 0% | 880 in 2030+0.2%/yr |
| Missouri | 13 | 810+0.3%/yr | +0.3%/yr | 1.31.8× | 0% | 810 in 2030+0.1%/yr |
| Georgia | 14 | 800−3.2%/yr | −3.2%/yr | 0.91.2× | 0% | 1,030 in 2030+4.3%/yr |
| Illinois | 12 | 791−1.1%/yr | −1.1%/yr | 0.60.8× | 0% | 930 in 2030+2.8%/yr |
| Virginia | 10 | 705−0.8%/yr | −0.8%/yr | 0.70.9× | 0% | 920 in 2030+4.6%/yr |
| Massachusetts | 8 | 640+1.2%/yr | +1.2%/yr | 0.70.9× | 0% | 1,240 in 2030+12%/yr |
| Arizona | 15 | 620−1%/yr | −1%/yr | 0.81.1× | 0% | 820 in 2030+4.8%/yr |
| North Carolina | 13 | 605−3.6%/yr | −3.6%/yr | 0.60.8× | 0% | 850 in 2030+5.9%/yr |
| Michigan | 3 | 585−8.8%/yr | −8.8%/yr | 0.70.9× | 0% | 540 in 2030−1.4%/yr |
| Indiana | 9 | 580−0.9%/yr | −0.9%/yr | 0.81.1× | 0% | 630 in 2030+1.3%/yr |
| Washington | 11 | 544+0.4%/yr | +0.4%/yr | 0.71.0× | 0% | 760 in 2030+5.7%/yr |
| Tennessee | 11 | 544+0.6%/yr | +0.6%/yr | 0.81.0× | 0% | 670 in 2030+3.5%/yr |
| Colorado | 10 | 529+3.9%/yr | +3.9%/yr | 1.11.5× | 0% | 750 in 2030+6.1%/yr |
| South Carolina | 8 | 517+0.1%/yr | +0.1%/yr | 0.81.0× | 0% | 620 in 2030+3%/yr |
| New Jersey | 7 | 492+0.3%/yr | +0.3%/yr | 0.50.6× | 0% | 540 in 2030+1.6%/yr |
| Wisconsin | 6 | 452−0.5%/yr | −0.5%/yr | 0.81.1× | 0% | 590 in 2030+4.6%/yr |
| Kentucky | 6 | 403−5.9%/yr | −5.9%/yr | 0.91.2× | 0% | 430 in 2030+1%/yr |
| Maryland | 9 | 381−0.3%/yr | −0.3%/yr | 0.40.6× | 0% | 520 in 2030+5.3%/yr |
| Alabama | 4 | 373−3%/yr | −3%/yr | 0.81.1× | 0% | 430 in 2030+2.3%/yr |
| Louisiana | 4 | 371−4.8%/yr | −4.8%/yr | 0.91.2× | 0% | 300 in 2030−3.6%/yr |
| Minnesota | 3 | 341−4.9%/yr | −4.9%/yr | 0.81.0× | 0% | 500 in 2030+6.7%/yr |
| Oregon | 3 | 328−6.4%/yr | −6.4%/yr | 0.81.1× | 0% | 390 in 2030+2.9%/yr |
| Oklahoma | 4 | 319−1.5%/yr | −1.5%/yr | 0.70.9× | 0% | 340 in 2030+0.8%/yr |
| Kansas | 4 | 304−0.4%/yr | −0.4%/yr | 0.81.0× | 0% | 450 in 2030+6.7%/yr |
| Mississippi | 3 | 297−1.9%/yr | −1.9%/yr | 0.81.1× | 0% | 300 in 2030+0.1%/yr |
| Nebraska | 5 | 255+2.2%/yr | +2.2%/yr | 1.01.3× | 0% | 370 in 2030+6.2%/yr |
| Arkansas | 1 | 248−7.6%/yr | −7.6%/yr | 0.70.9× | 0% | 260 in 2030+0.6%/yr |
| Utah | 3 | 239−2.8%/yr | −2.8%/yr | 1.11.5× | 0% | 170 in 2030−5.1%/yr |
| South Dakota | 6 | 218+2.8%/yr | +2.8%/yr | 1.72.3× | 0% | 300 in 2030+5.3%/yr |
| Connecticut | 4 | 214−7.4%/yr | −7.4%/yr | 0.60.9× | 0% | 200 in 2030−0.8%/yr |
| Idaho | 4 | 195−6.6%/yr | −6.6%/yr | 1.01.3× | 0% | 260 in 2030+4.7%/yr |
| Iowa | 3 | 193−6.6%/yr | −6.6%/yr | 0.40.6× | 0% | 300 in 2030+7.6%/yr |
| Nevada | 2 | 177−7.6%/yr | −7.6%/yr | 0.60.8× | 0% | 200 in 2030+2.1%/yr |
| Montana | 2 | 173+3.7%/yr | +3.7%/yr | 0.91.2× | 0% | 180 in 2030+0.7%/yr |
| New Hampshire | 1 | 142+1.5%/yr | +1.5%/yr | 0.60.8× | 0% | 220 in 2030+7.4%/yr |
| West Virginia | 2 | 134−13%/yr | −13%/yr | 0.60.9× | 0% | 100 in 2030−5.2%/yr |
| New Mexico | 1 | 129−1.8%/yr | −1.8%/yr | 0.60.8× | 0% | 130 in 2030+0.3%/yr |
Professional codes (what the surgeon bills): CPT 43280, 43281, 43282; the hospital bills MS-DRG 326, 327, 328.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 81 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 26 companies. The most active:
Product codes: GAG (stapler, surgical), GDW (staple, implantable). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 41% of the cases CMS names in Texas; 28 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Hernia repair | 2,306 | 187,629−3%/yr | −3%/yr | 210,200 in 2030+1.9%/yr |
| Cholecystectomy & appendectomy | 2,560 | 131,995−5.4%/yr | −5.4%/yr | 140,500 in 2030+1%/yr |
| Colorectal resection | 232 | 52,254−5.2%/yr | −5.2%/yr | 53,600 in 2030+0.4%/yr |
| Breast reconstruction | 66 | 13,660−6.4%/yr | −6.4%/yr | 17,400 in 2030+4.1%/yr |
| Bariatric surgery | 15 | 4,952−17%/yr | −17%/yr | 3,750 in 2030−4.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 2 companies reported engagement with surgeons in the covered states worth $109K in consulting, speaking, meals and travel tied to these products, about $292 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.